Summary
CGP 28 014 A is a specific inhibitor of catechol-O-methyl transferase (COMT). The effect on COMT was assessed with the levodopa test in 5 unmedicated subjects and after pretreatment with 200–600 mg CGP 28 014 p.o. Plasma concentrations of DOPA, 3-O-methyldopa (3OD), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid were measured. CGP 28 014 A decreased 3OMD not dose-related by 67% (p < 0.05). This, and an increase of DOPAC shows COMT inhibition by this compound in humans.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cotzias GC, Papvasiliou PS, Ginos JZ, Tolosa ES (1975) Treatment of Parkinson’s disease and allied conditions. In: Tower DB (ed) The nervous system, vol 2. The clinical neurosciences. Raven Press, New York, pp 323–329.
Maennistoe PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson’s disease?. TIPS 10:54–56.
Waldmeier PC, Feldrauer J-J, Hauser K, Bittiger H, Bischoff S, von Sprecher G (1990) CGP 28 014 A, a new non-catecholic COMT inhibitor. Naunyn-Schmie-debergs Arch Pharmacol 386 [Suppl]: R97.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag
About this paper
Cite this paper
Bieck, P., Nilsson, E., Antonin, K.H. (1990). Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects. In: Riederer, P., Youdim, M.B.H. (eds) Amine Oxidases and Their Impact on Neurobiology. Journal of Neural Transmission, vol 32. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9113-2_53
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9113-2_53
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82239-5
Online ISBN: 978-3-7091-9113-2
eBook Packages: Springer Book Archive